Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
This table compares Lipella Pharmaceuticals and Bicara Therapeutics’ net margins, return on equity and return on assets.
This is a summary of recent recommendations for Lipella Pharmaceuticals and Bicara Therapeutics, as reported by MarketBeat.com.
This table compares Lipella Pharmaceuticals and Bicara Therapeutics”s revenue, earnings per share (EPS) and valuation.
Bicara Therapeutics has lower revenue, but higher earnings than Lipella Pharmaceuticals.
74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bicara Therapeutics beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Receive News & Ratings for Lipella Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.…Read more by Defense World Staff